PRIMATE MODEL EVALUATION OF A TISSUE ENGINEERED HEART VALVE
PRIMATE MODEL EVALUATION OF A TISSUE ENGINEERED HEART VALVE
批准号:
8357672
负责人:
Richard A Hopkins
金额:
$0.1万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-05-01 至 2012-04-30
关键词:
AllograftingBiologicalBiologyCardiovascular systemCellsChildChronicClinicalComplexEngineeringEvaluationExcisionFundingGrantHeart ValvesHumanImmuneInfantInflammatoryLungMediatingModelingNational Center for Research ResourcesPapioPatientsPerformancePrimatesPrincipal InvestigatorProcessResearchResearch InfrastructureResearch Project GrantsResourcesSafetySheepSourceStructural ProteinTestingTherapeuticTissue EngineeringTranslational ResearchTransplantationUnited States National Institutes of HealthXenograft procedurecostdesignimmunogenicin vivonovelpreclinical safetyresponsesafety testingscaffoldsemilunar valvetoolyoung adult
中文摘要
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
这一转化性研究项目是由于需要开发新的评估工具来评估用于婴儿、儿童和年轻人的组织工程生物心脏瓣膜的临床前安全性。绵羊的慢性体内研究可能不足以充分评估灵长类动物特有的复杂生物学、免疫和炎症介导的反应,这些都是预计将显著影响人类临床使用的组织工程生物心脏瓣膜的安全性、性能和治疗持久性的关键因素。根据定义,这种组织工程心血管结构既包括细胞(来自患者/接受者),也包括结构蛋白(来自供者心脏瓣膜)。待测试的典型组织工程带瓣肺管道支架由同种异体移植(同种移植;即用于原位移植的狒狒)或异种移植(人类半月瓣)支架组成。这两种类型的测试阀都将被设计成能够去除供体细胞并降低抗原性(使用我们新的脱细胞工艺)。这项设计将测试去细胞构建的安全性,以及同种异体移植物(PAPIO)与异种移植物(人)结构蛋白的免疫原性和促炎潜能。
英文摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
This translational research project is prompted by the need to develop new evaluative tools to assess the preclinical safety of tissue engineered biological heart valves intended for use in infants, children and young adults. Chronic in vivo studies in sheep may not be sufficient to adequately evaluate primate-specific complex biology, immune and inflammatory-mediated responses that are critical factors expected to significantly impact the safety, performance and therapeutic durability of a tissue engineered biological heart valve for human clinical use. Such a tissue engineered cardiovascular construct, by definition, includes both cells (derived from the patient/recipient), and structural proteins (derived from the donor heart valve). The putative prototypical tissue engineered pulmonary valved conduit scaffold to be tested consists of either an allograft (homograft; ie, baboon species for orthotopic transplant) or a xenograft (human semilunar valve) scaffold. Both test valve types will have been engineered to effect removal of donor cells and reduce antigenicity (using our novel decellularization process). This design will test the safety of the acellular construct and the immunogenic and proinflammatory potential of allograft (papio) versus xenograft (human) structural proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PRIMATE MODEL EVALUATION OF A TISSUE ENGINEERED HEART VALVE
-
批准号:8172689
-
项目类别:
-
资助金额:$2.13万
-
财政年份:2010
-
负责人:Richard A Hopkins
-
依托单位:
PRIMATE MODEL EVALUATION OF A TISSUE ENGINEERED HEART VALVE
-
批准号:7957944
-
项目类别:
-
资助金额:$1.39万
-
财政年份:2009
-
负责人:Richard A Hopkins
-
依托单位:
BIOENGINEERED HEART VALVES: BABOON IMPLANT FEASIBILITY STUDY
-
批准号:7957943
-
项目类别:
-
资助金额:$0.82万
-
财政年份:2009
-
负责人:Richard A Hopkins
-
依托单位:
海外基金